ALK and non-small cell lung carcinoma: For advanced non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) positivity, ALK-tyrosine kinase inhibitors (ALK-TKIs) are considered the preferred first-line treatment option (Mok et al., 2020).